APA (7th ed.) Citation

Sharman, J., Liberati, A. M., Santucci Silva, R., Aurer, I., Robbins, J., Rosenberg, J. A., . . . Alcasid, A. (2018). A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL). Blood, 132(Supplement 1), 394. https://doi.org/10.1182/blood-2018-99-111248

Chicago Style (17th ed.) Citation

Sharman, Jeff, Anna Marina Liberati, Rodrigo Santucci Silva, Igor Aurer, Jeffery Robbins, Julie Ann Rosenberg, Tahira Khan, and Ann Alcasid. "A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)." Blood 132, no. Supplement 1 (2018): 394. https://doi.org/10.1182/blood-2018-99-111248.

MLA (9th ed.) Citation

Sharman, Jeff, et al. "A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)." Blood, vol. 132, no. Supplement 1, 2018, p. 394, https://doi.org/10.1182/blood-2018-99-111248.